A Phase 3 interventional study of Nalmefene hydrochloride in Alcohol Dependence, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 7 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-07-20.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing nalmefene in Alcoholism — none open to participants now, none under way, none of them phase 3. nalmefene · Alcoholism.
Among the 12 studies testing nalmefene in Alcoholism, this one is the 5th largest by enrollment, is one of 4 that started in 2015, is one of 6 in phase 3, and was the 7th registered.
1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.
Browse Alcoholism studies →None of the 12 studies testing nalmefene in Alcoholism is open now. The open studies under Alcoholism, anywhere →
nalmefene: first FDA approval 1995 (REVEX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 4 started in 2015.
This study's enrollment of 405 is above the median of 88 across 1,430 interventional studies indexed under Alcoholism.
Median enrollment 212 across the 12 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 6 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Otsuka Holdings Co., Ltd. has 5 studies filed under Alcoholism — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing nalmefene in Alcoholism, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The long-term safety and efficacy of nalmefene hydrochloride at 20 mg in patients with alcohol dependence will be evaluated in a multicenter, open-label, uncontrolled trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
As-needed; tablets, orally
Drug: Nalmefene hydrochloride
Number of Participants With Adverse Events
Time frame: 24-week treatment period
Change in the Number of Heavy Drinking Days (HDDs) From Baseline
Time frame: Week 24
Change in Total Alcohol Consumption (TAC) From Baseline
Time frame: Week 24
| Milestone | Nalmefene 20 mg in the lead-in Study | Nalmefene 10 mg in the lead-in Study | Placebo in the lead-in Study |
|---|---|---|---|
| Started | 137 | 94 | 172 |
| Completed | 126 | 84 | 133 |
| Not completed | 11 | 10 | 39 |
| Withdrew: Withdrawal by subject | 4 | 8 | 5 |
| Withdrew: Adverse event | 7 | 2 | 32 |
| Withdrew: Physician decision | 0 | 0 | 2 |
| Number of participants | Nalmefene 20 mg in the lead-in Study | Nalmefene 10 mg in the lead-in Study | Placebo in the lead-in Study |
|---|---|---|---|
| Number of Participants With Adverse Events | 96 | 67 | 141 |
| days/month | Nalmefene 20 mg in the lead-in Study | Nalmefene 10 mg in the lead-in Study | Placebo in the lead-in Study |
|---|---|---|---|
| Change in the Number of Heavy Drinking Days (HDDs) From Baseline | -15.09 ± 0.77 | -17.15 ± 0.94 | -16.35 ± 0.70 |
| g/day | Nalmefene 20 mg in the lead-in Study | Nalmefene 10 mg in the lead-in Study | Placebo in the lead-in Study |
|---|---|---|---|
| Change in Total Alcohol Consumption (TAC) From Baseline | -53.20 ± 2.29 | -57.93 ± 2.77 | -55.77 ± 2.06 |
Collected over 24-week treatment period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Total | 0/403 (0%) | 3/403 (0.7%) | 209/403 (51.9%) |
| Event | Total |
|---|---|
| GastroenteritisInfections and infestations | 1/403 |
| DehydrationMetabolism and nutrition disorders | 1/403 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/403 |
| Event | Total |
|---|---|
| NauseaGastrointestinal disorders | 79/403 |
| NasopharyngitisInfections and infestations | 62/403 |
| DizzinessNervous system disorders | 39/403 |
| HeadacheNervous system disorders | 29/403 |
| MalaiseGeneral disorders | 26/403 |
| SomnolenceNervous system disorders | 26/403 |
| VomitingGastrointestinal disorders | 25/403 |
| Abdominal discomfortGastrointestinal disorders | 23/403 |
| InsomniaPsychiatric disorders | 20/403 |
Safety analysis set, which included all patients who received at least one dose of study medication during the 24-week treatment period in the extension study.
| Age, Categorical(Participants) | Nalmefene 20 mg in the lead-in Study | Nalmefene 10 mg in the lead-in Study | Placebo in the lead-in Study | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 120 | 85 | 154 | 359 |
| >=65 years | 17 | 9 | 18 | 44 |
| Age, Customized(years) | Nalmefene 20 mg in the lead-in Study | Nalmefene 10 mg in the lead-in Study | Placebo in the lead-in Study | Total |
|---|---|---|---|---|
| Mean | 50.0 ± 11.7 | 50.1 ± 11.0 | 48.5 ± 11.0 | 49.4 ± 11.2 |
| Sex: Female, Male(Participants) | Nalmefene 20 mg in the lead-in Study | Nalmefene 10 mg in the lead-in Study | Placebo in the lead-in Study | Total |
|---|---|---|---|---|
| Female | 33 | 19 | 64 | 116 |
| Male | 104 | 75 | 108 | 287 |
| Race/Ethnicity, Customized(Participants) | Nalmefene 20 mg in the lead-in Study | Nalmefene 10 mg in the lead-in Study | Placebo in the lead-in Study | Total |
|---|---|---|---|---|
| Japanese | 137 | 94 | 172 | 403 |
| Region of Enrollment(Participants) | Nalmefene 20 mg in the lead-in Study | Nalmefene 10 mg in the lead-in Study | Placebo in the lead-in Study | Total |
|---|---|---|---|---|
| Japan | 137 | 94 | 172 | 403 |
| Heavy Drinking Days (HDDs)(days/month) | Nalmefene 20 mg in the lead-in Study | Nalmefene 10 mg in the lead-in Study | Placebo in the lead-in Study | Total |
|---|---|---|---|---|
| Mean | 22.54 ± 6.70 | 24.38 ± 5.10 | 22.70 ± 6.54 | 23.04 ± 6.32 |
| Total Alcohol Consumption (TAC)(g/day) | Nalmefene 20 mg in the lead-in Study | Nalmefene 10 mg in the lead-in Study | Placebo in the lead-in Study | Total |
|---|---|---|---|---|
| Mean | 94.10 ± 34.43 | 94.16 ± 32.60 | 92.30 ± 41.03 | 93.35 ± 36.90 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2015 to primary completion in Jan 2017, 18 months.
Results were first posted in Jul 2020, 3 years 6 months after primary completion.
Of 25 phase 3 interventional studies under Alcoholism, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nalmefene
Otsuka Pharmaceutical Co., Ltd. →